ESLA

+ Watchlist + Portfolio

Estrella Immunopharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.74
52-Week Range: $0.68 – $3.15
Market Cap: $32.41M
P/E (TTM): —
EPS (TTM): -0.25
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -251.86%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.20
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-6.79M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $32.26M

ESLA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.39M	$10.45M	$4.11M	$10.25M
Selling, General & Admin	$296.25K	$663.19K	$3.20M	$2.81M
Operating Expenses	$1.69M	$11.11M	$7.31M	$13.06M
Operating Income	-$1.69M	-$11.11M	-$7.31M	-$13.06M
EBITDA	-$1.69M	-$11.11M	-$7.31M	-$13.06M
Pretax Income	-$1.69M	-$11.11M	-$7.31M	-$13.06M
Income Tax	$0.00	$0.00	$1.63K	$838.00
Net Income	-$1.69M	-$11.11M	-$7.31M	-$13.06M
Diluted EPS	-0.05	-0.32	-0.27	-0.35
Diluted Shares	35.20M	35.20M	27.10M	36.82M

ESLA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.09M	$2.48M	$4.17M	$1.38M
Receivables	—	$273.07K	$288.76K	$292.67K
Current Assets	$4.92M	$2.75M	$4.45M	$1.68M
Total Assets	$4.92M	$3.03M	$4.45M	$3.18M
Current Liabilities	$946.68K	$9.76M	$180.70K	$13.54M
Total Liabilities	$5.96M	$14.77M	$180.70K	$13.54M
Retained Earnings	-$1.07M	-$12.19M	-$19.50M	-$36.99M
Shareholders' Equity	-$1.04M	-$11.74M	$4.27M	-$10.37M
Working Capital	$3.97M	-$7.01M	$4.27M	-$11.87M

ESLA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.44M	-$1.34M	-$16.07M	-$1.79M
Free Cash Flow	-$1.44M	-$1.34M	-$16.07M	-$1.79M
Stock-Based Compensation	$129.97K	$409.60K	$1.19M	$618.97K
Investing Cash Flow	$0.00	-$273.07K	$4.96M	—
Financing Cash Flow	$5.53M	$0.00	$12.79M	$2.25M
Share Repurchases	—	$0.00	-$354.44K	-$29.46K
Net Change in Cash	—	-$1.61M	$1.69M	$467.39K

ESLA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.41M	$4.66M	$4.15M	$25.41K	$1.40M
Selling, General & Admin	$694.11K	$883.73K	$648.51K	$587.78K	$891.79K
Operating Expenses	$2.10M	$5.54M	$4.80M	$613.20K	$2.29M
Operating Income	-$2.10M	-$5.54M	-$4.80M	-$613.20K	-$2.29M
EBITDA	-$2.10M	-$5.54M	-$4.80M	-$613.20K	-$2.29M
Pretax Income	-$2.10M	-$5.54M	-$4.80M	-$613.20K	-$2.29M
Income Tax	$13.00	$850.00	$0.00	-$25.00	$0.00
Net Income	-$2.10M	-$5.54M	-$4.80M	-$613.17K	-$2.29M
Diluted EPS	-0.06	-0.15	-0.13	—	-0.05
Diluted Shares	36.19M	36.17M	37.10M	—	42.12M

ESLA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$421.47K	$1.32M	$1.63M	$1.38M	$1.93M
Receivables	$522.79K	$163.93K	$396.90K	$292.67K	$229.79K
Current Assets	$944.27K	$1.48M	$2.02M	$1.68M	$2.16M
Total Assets	$2.44M	$2.98M	$3.52M	$3.18M	$3.66M
Current Liabilities	$4.28M	$9.08M	$13.36M	$13.54M	$8.93M
Total Liabilities	$4.28M	$9.08M	$13.36M	$13.54M	$8.93M
Retained Earnings	-$26.03M	-$31.58M	-$36.38M	-$36.99M	-$39.28M
Shareholders' Equity	-$1.83M	-$6.09M	-$9.84M	-$10.37M	-$5.27M
Working Capital	-$3.33M	-$7.59M	-$11.34M	-$11.87M	-$6.77M

ESLA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$465.98K	-$414.88K	-$727.33K	-$177.49K	-$6.70M
Free Cash Flow	-$465.98K	-$414.88K	-$727.33K	-$177.49K	-$6.70M
Stock-Based Compensation	$159.09K	$159.10K	$152.42K	$148.36K	$146.71K
Financing Cash Flow	-$29.46K	$1.31M	$1.04M	-$64.82K	$7.24M
Share Repurchases	-$29.46K	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$495.44K	$895.12K	$310.02K	-$242.31K	$543.10K

Market Snapshot

About

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapy treatments for cancer patients. The company's pipeline includes novel therapeutic approaches targeting tumor microenvironments and immune checkpoint pathways to enhance the body's natural cancer-fighting capabilities. Estrella conducts clinical trials to evaluate the safety and efficacy of its investigational drugs across multiple cancer indications. The company collaborates with research institutions and clinical centers to advance its development programs toward regulatory approval.